Cue Biopharma Inc

0.00 (0.00%)
Earnings Announcements

Cue Biopharma Reports Q3 Loss Per Share Of $0.34

Published: 11/17/2020 21:10 GMT
Cue Biopharma Inc (CUE) - Cue Biopharma Reports Third Quarter 2020 Results and Cue-101 Phase 1 Dose Escalation Trial Updates.
Cue Biopharma Inc - Qtrly Loss per Share $0.34.
Cue Biopharma Inc - Believe Cash, Cash Equivalents Will Allow US to Support Clinical Development of Our Lead Asset Cue-101 Into Q2 of 2022.
Revenue is expected to be $1.49 Million
Adjusted EPS is expected to be -$0.35

Next Quarter Revenue Guidance is expected to be $1.07 Million
Next Quarter EPS Guidance is expected to be -$0.40

More details on our Analysts Page.